Figure 4: Percentage of Patients With 35% and 50% Reduction in FIAS and TCS, Patients With Coexisting ASD
Percentage of Patients With 35% and 50% Reduction in FIAS and TCS by Time Point, Patients With Coexisting ASD at Baseline
Format
PNG
Source
Zynerba Pharmaceuticals, Inc.